... Food and Drug Administration Fenfluramine Hcl (Fintepla) Provides Long‐Term Clinically Meaningful Reduction in Seizure Frequency: Analysis of an Ongoing Open‐Label Extension Study — Epilepsia Seizure Rescue Medications — Epilepsy Foundation Seizure Emergencies — Epilepsy Foundation Seizure Action Plans — Epilepsy Foundation ...
Dravet Syndrome Treatment: Knowing Your Options
... Food and Drug Administration Fenfluramine Hcl (Fintepla) Provides Long‐Term Clinically Meaningful Reduction in Seizure Frequency: Analysis of an Ongoing Open‐Label Extension Study — Epilepsia Seizure Rescue Medications — Epilepsy Foundation Seizure Emergencies — Epilepsy Foundation Seizure Action Plans — Epilepsy Foundation ...
... Placebo-Controlled Phase 3 Trial — The Lancet Long-Term Safety and Efficacy of Add-on Cannabidiol in Patients With Lennox Gastaut Syndrome: Results of a Long-Term Open-Label Extension Trial — Epilepsia Fenfluramine Indication Expansion To Include Lennox-Gastaut Syndrome Submitted to FDA — Practical Neurology Highlights of Prescribing Information: Fintepla ...
Lennox-Gastaut Syndrome: Treatment Options Explained
... Placebo-Controlled Phase 3 Trial — The Lancet Long-Term Safety and Efficacy of Add-on Cannabidiol in Patients With Lennox Gastaut Syndrome: Results of a Long-Term Open-Label Extension Trial — Epilepsia Fenfluramine Indication Expansion To Include Lennox-Gastaut Syndrome Submitted to FDA — Practical Neurology Highlights of Prescribing Information: Fintepla ...
Join
